PDGFRA Antibody for Soft Tissue Sarcoma

Lillian R. Klug, Michael C. Heinrich

Research output: Contribution to journalShort surveypeer-review

6 Scopus citations


Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.

Original languageEnglish (US)
Pages (from-to)555
Number of pages1
Issue number4
StatePublished - Feb 9 2017

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'PDGFRA Antibody for Soft Tissue Sarcoma'. Together they form a unique fingerprint.

Cite this